ENDRA Life Sciences Inc. (NASDAQ:NDRA) Short Interest Update

ENDRA Life Sciences Inc. (NASDAQ:NDRA) saw a significant growth in short interest in February. As of February 27th, there was short interest totaling 154,773 shares, a growth of 163.6% from the February 12th total of 58,719 shares. Based on an average daily volume of 511,270 shares, the days-to-cover ratio is currently 0.3 days. Approximately 22.8% of the company’s stock are short sold. Approximately 22.8% of the company’s stock are short sold. Based on an average daily volume of 511,270 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Investors Weigh In On ENDRA Life Sciences

An institutional investor recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC purchased a new position in ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences comprises about 0.9% of Altium Capital Management LLC’s holdings, making the stock its 17th biggest position. Altium Capital Management LLC owned 6.92% of ENDRA Life Sciences at the end of the most recent quarter. Hedge funds and other institutional investors own 1.19% of the company’s stock.

ENDRA Life Sciences Stock Performance

Shares of ENDRA Life Sciences stock traded up $0.20 during mid-day trading on Friday, hitting $3.47. 7,273 shares of the stock were exchanged, compared to its average volume of 280,025. ENDRA Life Sciences has a 12 month low of $2.90 and a 12 month high of $11.96. The company has a 50-day simple moving average of $4.00 and a 200 day simple moving average of $4.89. The company has a market capitalization of $2.60 million, a P/E ratio of -0.13 and a beta of -0.08.

Analyst Ratings Changes

Several equities research analysts recently issued reports on NDRA shares. Wall Street Zen upgraded ENDRA Life Sciences to a “sell” rating in a report on Saturday, November 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of ENDRA Life Sciences in a research note on Wednesday, January 21st. Finally, Ascendiant Capital Markets cut their price objective on shares of ENDRA Life Sciences from $38.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, December 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, ENDRA Life Sciences currently has a consensus rating of “Hold” and an average target price of $30.00.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.